title: Colesevelam for the management of type 2 diabetes.
abstract: BACKGROUND
  At present there are 246 million individuals with diabetes worldwide and this is anticipated to grow to 380 million by 2025. Internationally, the control of glucose and cholesterol to targets is less than optimal in patients with type 2 diabetes.
  
  
  OBJECTIVE
  To summarize the chemistry, pharmacokinetics and metabolism of colesevelam hydrochloride, and review its clinical efficacy and toxicity in the management of type 2 diabetes.
  
  
  METHODS
  Literature search of colesevelam studies and abstracts assessing the benefits in managing type 2 diabetes mellitus.
  
  
  CONCLUSIONS
  Several studies have demonstrated the efficacy of colesevelam hydrochloride in the treatment of hyperglycemia associated with type 2 diabetes. The established dual role of cholesterol lowering and glucose lowering needs to be considered when managing patients with type 2 diabetes.
authors.affiliation: Oregon State University, Department of Pharmacy Practice, Portland, OR 97239, USA. marrsj@ohsu.edu
authors.forename: Joel C
authors.initials: JC
authors.lastname: Marrs
mesh_terms: D000499:Allylamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D000069472:Colesevelam Hydrochloride; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000209:etiology
chemical_list: D000924:Anticholesteremic Agents; D001786:Blood Glucose; D000499:Allylamine; D002784:Cholesterol; D000069472:Colesevelam Hydrochloride